Tranche Update on Amphastar Pharmaceuticals, Inc.'s Equity Buyback Plan announced on November 8, 2016.
May 09, 2023 at 04:54 pm EDT
Share
From January 1, 2023 to March 31, 2023, the company has repurchased 263,131 shares, representing 0.55% for $8.01 million. With this, the company has completed the repurchase of 9,002,547 shares, representing 19.1% for $178.77 million under the buyback announced on November 8, 2016.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.
AMPHASTAR PHARMACEUTICALS, INC. 
